Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2 and Heads Up studies

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Silverberg, Jonathan, I [2 ]
Calimlim, Brian M. [3 ]
Liu, Yingyi [3 ]
Platt, Andrew [3 ]
Thyssen, Jacob P. [4 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] George Washington Univ, Dept Dermatol, Sch Med & Hlth Sci, Washington, DC USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
upadacitinib; dupilumab; atopic dermatitis; skin clearance; EASI;
D O I：
10.1093/bjd/ljac140.047
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
355
引用
收藏
页数：2
相关论文
共 50 条
  • [21] UPADACITINIB VERSUS DUPILUMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF THE HEADS UP PHASE 3 TRIAL
    Blauvelt, Andrew
    Teixeira, Henrique D.
    Simpson, Eric L.
    Costanzo, Antonio
    De Bruin-Weller, Marjolein
    Barbarot, Sebastien
    Prajapati, Vimal H.
    Lio, Peter
    Hu, Xiaofei
    Wu, Tianshuang
    Liu, John
    Ladizinski, Barry
    Chu, Alvina D.
    Eyerich, Kilian
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 62 - 62
  • [22] Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study
    Thyssen, Jacob P.
    Rosmarin, David
    Costanzo, Antonio
    Warren, Richard
    Chu, Chia-Yu
    Chovatiya, Raj
    Ladizinski, Barry
    Hu, Xiaofei
    Liu, Yingyi
    Calimlim, Brian
    Nduaka, Chudi
    Vigna, Namita
    Armstrong, April
    DERMATOLOGY, 2025, 241 (01) : 10 - 18
  • [23] Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
    Prajapati, Vimal H.
    Bunick, Christopher G.
    Eyerich, Kilian
    Gold, Linda Stein
    Galimberti, Fabrizio
    Calimlim, Brian
    Teixeira, Henrique
    Hu, Xiaofei
    Yang, Yang
    Sancho, Cristina
    Grada, Ayman
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [24] Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Prajapati, Vimal H.
    Rosmarin, David
    Shumack, Stephen
    Calimlim, Brian M.
    Takemoto, Shunya
    Hu, Xiaofei
    Ladizinski, Barry
    Warren, Richard B.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E81 - E81
  • [25] Upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the Heads Up phase III trial
    Blauvelt, A.
    Teixeira, H. D.
    Simpson, E. L.
    Costanzo, A.
    De Bruin-Weller, M.
    Barbarot, S.
    Prajapati, V. H.
    Lio, P.
    Hu, X.
    Wu, T.
    Liu, J.
    Ladizinski, B.
    Chu, A. D.
    Eyerich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E123 - E123
  • [26] Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from two pivotal, phase III, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)
    Guttman-Yassky, E.
    Teixeira, H. D.
    Simpson, E. L.
    Papp, K. A.
    Pangan, A. L.
    Blauvelt, A.
    Thaci, D.
    Chu, C. Y.
    Hong, H. C.
    Katoh, N.
    Paller, A. S.
    Calimlim, B.
    Gu, Y.
    Hu, X.
    Liu, M.
    Yang, Y.
    Tenorio, A. R.
    Chu, A. D.
    Irvine, A. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E62 - E62
  • [27] Effect of upadacitinib on SCORAD intensity items: analysis from the Measure Up 1 and Measure Up 2 studies
    Cameron, Michael
    Magnolo, Nina
    Prajapati, Vimal H.
    Haque, Adel
    Lee, Wan-Ju
    Altman, Katherine
    Platt, Andrew M.
    Lane, Michael C.
    Calimlim, Brian M.
    Taieb, Alain
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [28] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    de Bruin-Weller, Marjolein S.
    Papp, Kim A.
    Aoki, Valeria
    Paller, Amy S.
    Ofori, Sarah
    Tenorio, Allan R.
    Liu, Yingyi
    Liu, Jianzhong
    Chovatiya, Raj
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
  • [29] Achieving incrementally greater skin improvement thresholds with upadacitinib versus dupilumab in moderate-to-severe atopic dermatitis (AD): Heads Up study results
    Silverberg, Jonathan I.
    Eyerich, Kilian
    de Bruin-Weller, Marjolein
    Calimlim, Brian M.
    Platt, Andrew M.
    Wu, Tianshuang
    Ladizinski, Barry
    Thyssen, Jacob P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB134 - AB134
  • [30] Efficacy and safety of upadacitinib vs dupilumab treatment for moderate to severe atopic dermatitis in four body regions - Analysis from the Heads Up Study
    Thyssen, Jacob P.
    Rosmarin, David
    Costanzo, Antonio
    Warren, Richard B.
    Ladizinkski, Barry
    Hu, Xiaofei
    Nduaka, Chudi
    Vigna, Namita
    Armstrong, April
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 998 - 999
12345